Cytomegalovirus retinitis [induction and maintenance
treatment in patients with AIDS]
▶BY MOUTH
▶Adult: Initially 900 mg twice daily for 21 days, then
maintenance 900 mg daily, induction regimen may be
repeated if retinitis progresses
Prevention of cytomegalovirus disease [following solid
organ transplantation from a cytomegalovirus positive
donor]
▶BY MOUTH
▶Adult: 900 mg daily for 100 days (for 100–200 days
following kidney transplantation), to be started within
10 days of transplantation
DOSE EQUIVALENCE AND CONVERSION
Infection
▶Oral valganciclovir 900 mg twice daily is equivalent to
intravenous ganciclovir 5 mg/kg twice daily.
PDF page 697
Abnormally low haemoglobin count
(consult product literature). abnormally low neutrophil
count (consult product literature). abnormally low platelet
count (consult product literature)
PDF page 697
History of cytopenia. potential carcinogen
(including long-term carcinogenicity). potential teratogen
(including long-term teratogenicity). radiotherapy
PDF page 697
Contra-indicated in
patients hypersensitive to ganciclovir, aciclovir, or
valaciclovir.
PDF page 697
Valganciclovir is a pro-drug of ganciclovir.
Flavours of oral liquid formulations may include tutti-
frutti.
l HANDLING AND STORAGE Manufacturer advises
reconstituted powder for oral solution should be stored in
a refrigerator (2–8°C) for up to 49 days.
Caution in handling Valganciclovir is a potential teratogen
and carcinogen. Manufacturer advises caution when
handling the powder, reconstituted solution, or broken
tablets and avoid inhalation of powder; if contact with skin
or mucous membranes occurs, wash thoroughly with soap
and water; rinse eyes thoroughly with plain water.
PDF pages 697, 698
